Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2023-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess trough, TREM-1 levels and efficacy of IFX and ADA in IBD patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients

NCT05720221

IBD

COMPLETED

Therapeutic Monitoring of Infliximab and Adalimumab

NCT06033469

Inflammatory Bowel Diseases

UNKNOWN

Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study

NCT02450513

Crohn's Disease

COMPLETED

Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)

NCT01971970

Inflammatory Bowel Diseases

COMPLETED

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

NCT03452501

Inflammatory Bowel Diseases Crohn Disease Fistulizing Crohn's Disease +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1\. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour University 2. All participants agree to take part in this clinical study, will agree to provide an informed written consent 3. Patients will be divided into 2 treatment groups \[group 1 (n=20): patients will receive IFX\], \[group 2 (n=20): patients will receive ADA\]. 4. Statistical tests appropriate to the study will be conducted to evaluate significance of results 5. Results, conclusion, discussion and recommendations will be given

* Type of Study: prospective study for IBD patients receiving either adalimumab or infliximab.
* Study Setting: The Inflammatory Bowel disease outpatient clinic, Tropical Medicine department, Ain Shams University Hospitals.
* Sample Size: Study will be conducted on 40 patients with Inflammatory Bowel Disease (IBD).
* Study procedure

1. Laboratory investigations

a) At baseline, all patients will be subjected to i. full history taking regarding: Loss of appetite, abdominal pain, number of motions, bleeding per rectum, number of attacks per year, need for hospitalization per year, Loss of weight, extra intestinal manifestations, anemic manifestations, drug history, ii. Testing the viral markers (HCV Ab, HBs Ag, HB core IgG, HIV) and Tuberculine test or Quantifferon test. (To Exclude latent TB) b) At Baseline and in follow ups, patient will be assessed for the following laboratory investigations: i. Complete blood count (CBC). ii. Liver profile (albumin, INR, total \& direct bilirubin, AST, ALT) iii. Kidney function tests e.g BUN and creatinine. iv. Inflammatory Markers (C-reactive protein (CRP), estimated sedimentation Ratio (ESR)).

v. Stool analysis (WBC's, RBC's, Parasite) vi. Stool culture and sensitivity. vii. Urine analysis. c) Trough concentration of ADA and IFX will be assessed after reaching steady state levels.

d) TREM-1 levels will be measured for all patients.
2. Endoscopic intervention

1. Colonoscopy with terminal ileoscopy with assessment according to Mayo score (loss of vascular pattern, presence of polyps, opacity of mucosa, bleeding on touch, excess exudates, diffuse ulceration, masses, pseudo polyps, site of involvement, linear ulcers, cobblestone appearance, conclusion)
2. Histopathological examination: (aggregates of PMN's, cryptitis, infiltration of lamina propria, granuloma, depletion of goblet cells, thickened muscularis mucosa, dysplasia \& it's degree, malignancy)

Efficacy and safety Assessments

* Target response will be measured according to mucosal healing, ESR and CRP then patients will be reassessed by ECCO guidelines.
* Safety of drugs will be assessed by the monthly follow up of CBC, Liver functions and kidney functions.
* Patients will be asked for the occurrence of any sides in the monthly follow up visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

prospective study for IBD patients receiving either adalimumab (group 1) or infliximab (group 2).

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Randomized controlled

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infliximab.

group 1 (n=20): patients will receive IFX,

Group Type ACTIVE_COMPARATOR

Infliximab

Intervention Type DRUG

group 1 (n=20): patients will receive IFX

Adalimumab.

group 2 (n=20): patients will receive ADA

Group Type ACTIVE_COMPARATOR

Adalimumab

Intervention Type DRUG

group 2 (n=20): patients will receive ADA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Infliximab

group 1 (n=20): patients will receive IFX

Intervention Type DRUG

Adalimumab

group 2 (n=20): patients will receive ADA

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IFX ADA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult patients between 18 years and 80 years.
2. Patients having moderate to severe IBD according to European Crohn's and colitis organization (ECCO) guidelines.
3. IBD patients receiving either IFX or ADA.

Exclusion Criteria

1. Patients missed one-year follow-up or with missed data.
2. Patients having mild IBD according to ECCO guidelines.
3. Patients having any of the Contraindications to the biological Therapy e.g.: latent TB, viral or fungal or bacterial infection.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No